20 October 2025 in Lung Cancer
Primary lung carcinomas are extremely rare in childhood, resulting in limited knowledge of their biology and potential therapeutic targets. Whole genome sequencing analysis was performed on 14 patients, thereof 13 pediatric patients. The cohort was grouped into pulmonary mucoepidermoid carcinoma (PMEC) and lung adenocarcinoma (LUAD) with an additional sample being adenosquamous carcinoma (ASC). DNA of tumor and normal tissue were isolated from FFPE and sequenced on a high-throughput sequencer. Data analysis was performed with an in-house validated data analysis pipeline. In the group of pediatric LUAD and ASC, ALK::EML4 fusions were confirmed in three of six tumors, prompting ALK-targeted treatment. We also found mutations frequently occurring in adult LUAD, such as TP53 (n = 3), KRAS and EGFR (each n = 1), but not other established druggable alterations. No smoking-related signatures were observed. One LUAD sample had a homologous recombination deficiency with a high amount of copy number alterations. In the PMEC group (n = 7), we found MAML2 fusions in all patients. Pathogenic germline variants and elevated polygenic risk scores for lung cancer were not detected in both groups. This study provides crucial insights into the genomic landscape across different types of pediatric lung cancer. We observed frequent presence of ALK fusions in pediatric LUAD + ASC, which are less common in adult LUAD. Other alterations in this subgroup showed resemblance with adult LUAD findings. In pediatric PMEC, we demonstrated the ubiquitous presence of MAML2 translocations. However, the conclusions of the study are limited due to the small sample size and potential artifacts from formalin-fixed paraffin-embedded samples. In summary, the results provide better understanding of the development of rare pediatric tumors and approaches for targeted therapies.
29 September 2026 in bioRxiv
Genomic events and their timing that grant a primary tumour the competence to disseminate remain poorly defined. We performed sequencing of 247 stage I/II primary cutaneous melanomas (CMs) and 60 matched metastases without intervening therapy from a prospectively followed registry cohort with a median followup of 92 months, integrating copy-number, mutational, protein and spatial-transcriptomic analyses. Relapse was not distinguished by oncogenic point mutations, which were largely shared between primaries and metastases, but by somatic copy-number alterations (SCNAs) and global chromosomal instability. We defined OncoCycle, a six-gene copy-number signature (amplification of CDK4 , MCL1 and CD276 ; biallelic loss of CDKN2A , CDKN2B and TP53BP1 ) that predicted relapse independently of established clinicopathological features in melanoma, and a pan-cancer analysis. In matched pairs, metastatic progression was driven by continued copy-number evolution and reduction in intra-tumoural heterogeneity, rather than by acquired point mutations, and OncoCycle alterations from primary tumours were preserved in metastasis seeding clones. Clonal reconstruction revealed both monoclonal and polyclonal metastasis seeding, and spatial transcriptomics resolved copy-number-defined metastatic subclones occupying and programming distinct immune and stromal niches. Thus, metastatic competence was primed early by focal SCNAs on a background of chromosomal instability, elaborated by continued copy-number evolution during dissemination and spatio-temporal interactions with the tumour-microenvironment.
27 October 2026 in Cancer Medicine
Precision oncology is based on comprehensive molecular characterization of a patient's tumor. This is mostly realized by next‐generation sequencing panels or exome sequencing. Data on the value of genome sequencing from formalin‐fixed paraffin embedded (FFPE) material in a clinical setting is still scarce. In this pilot, we generated datasets of matched exome and genome sequencing of FFPE tumor samples from 15 cancer patients to benchmark quality metrics, clinical feasibility, and added value for a molecular tumor board. Despite the reduced sequencing depth, diagnostic detection of small nucleotide variations, copy number variations, and complex biomarkers was maintained in genome sequencing compared to exome sequencing with the exception of hard‐to‐sequence regions. Evaluation by the local molecular tumor board identified additional treatment recommendations with high priority in 20% (3/15) of patients and additional molecular markers to support existing treatment recommendations in another 20% (3/15) of patients. Our work underscores the diagnostic superiority of genome sequencing even for FFPE samples and therefore supports its integration into clinical practice.